Zolpidem in Parkinson's disease
1997; Elsevier BV; Volume: 349; Issue: 9060 Linguagem: Inglês
10.1016/s0140-6736(05)62416-6
ISSN1474-547X
AutoresAntonio Daniele, Alberto Albanese, Guido Gainotti, B. Gregori, Paolo Bartolomeo,
Tópico(s)Neuroscience and Neuropharmacology Research
ResumoJankovic and Marsden 1 Jankovic J Marsden CD Therapeutic strategies in Parkinson's disease. in: Jankovic J Tolosa E Parkinson's disease and movement disorders. Urban and Schwarzenberg, Baltimore and Munich1988: 95-119 Google Scholar suggest that drugs that enhance neurotransmission of δ-aminobutyric acid (GABA) could be helpful in Parkinson's disease, but there is little evidence to support this claim. Zolpidem, an imidazopyridine short-acting hypnotic drug used to treat insomnia, shows high selectivity for the benzodiazepine subtype receptor BZ1, which is part of the GABAA-receptor complex. The highest density of zolpidem-binding sites is in the output structures of the basal ganglia: the ventral globus pallidus and the substantia nigra pars reticulata. 2 Langer SZ Arbilla S Scatton B Niddam R Dubois A Receptors involved in the mechanisms of action of zolpidem. in: Sauvanet JP Langer SZ Morselli PL Imidazopyridines in sleep disorders. Raven Press, New York1988: 55-70 Google Scholar We observed a 61-year-old woman with a 25-year history of Parkinson's disease who received zolpidem for insomnia. After the first 10 mg dose, she showed no drowsiness, but a substantial improvement in akinesia and rigidity. Such antiparkinsonian effects were similar to those of levodopa. Other hypnotics (triazolam, zopiclone) were ineffective. This patient received zolpidem (10 mg four times daily) without dopaminergic drugs for 5 years, with relief from Parkinsonian symptoms and no side-effects. We therefore conducted a double-blind, placebo-controlled crossover study of zolpidem in ten patients with clinically diagnosed Parkinson's disease. 3 Gibb WRG Lees AJ The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1988; 51: 745-752 Crossref PubMed Scopus (2842) Google Scholar
Referência(s)